PBRM1 and BAP1: novel genetic mutations in malignant transformation of craniopharyngioma-a case report

被引:1
|
作者
Tamura, Mitsuru [1 ]
Yokogami, Kiyotaka [1 ]
Watanabe, Takashi [1 ]
Kawano, Tomoki [1 ]
Muta, Junichiro [1 ]
Yamashita, Shinji [1 ]
Oguri, Nobuyuki [2 ]
Sato, Yuichiro [2 ]
Takeshima, Hideo [1 ]
机构
[1] Univ Miyazaki, Fac Med, Dept Neurosurg, 5200 Kihara, Kiyotake, Miyazaki 8891692, Japan
[2] Univ Miyazaki, Univ Miyazaki Hosp, Dept Diagnost Pathol, 5200 Kihara, Kiyotake, Miyazaki 8891692, Japan
关键词
Craniopharyngioma; Malignant transformation; BAP1; PBRM1; RENAL-CELL CARCINOMA;
D O I
10.1007/s10014-022-00444-3
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Malignant craniopharyngioma is especially rare, so the causes and genetic mutations associated with the malignant transformation have not been explained in detail. We investigated the molecular genetic characteristics of malignant transformation in craniopharyngioma. A 53-year-old man with a history of adamantinomatous craniopharyngioma presented with complaints of subcutaneous swelling. Magnetic resonance imaging showed a less enhanced intradural supra-sellar lesion and a heterogeneously well-enhanced extradural invasive lesion infiltrating the dura mater, brain, frontal bone, and subcutaneous tissue. Histopathological examination of the recurrent tumor revealed typical findings of both craniopharyngioma (intradural supra-sellar lesion) and malignant transformation, such as marked nuclear atypia with mitosis (invasive extradural lesion), which were not present in the primary tumor. A genetic panel test with the Oncopanel system was performed to investigate the genetic mutations responsible for the malignant transformation. Four genetic mutations were identified: CTNNB1 c.C98T, TP53 p.C135fs*35(PLS = 3 UPD/LOH), PBRM1 p.R1000*(PLS = 3 UPD/LOH), and BAP1 p.L650fs*5(PLS = 3 UPD/LOH). Sanger sequencing showed CTNNB1 in both the intradural supra-sellar and extradural invasive lesions, but TP53, PBRM1, and BAP1 only in the extradural invasive lesion. The genetic mutations of PBRM1 and BAP1 may be genetic factors in the malignant transformation of adamantinomatous craniopharyngioma.
引用
收藏
页码:40 / 44
页数:5
相关论文
共 50 条
  • [41] Meningiomas in Patients With Malignant Pleural Mesothelioma Harboring Germline BAP1 Mutations
    Hu, Zishuo, I
    Miettinen, Markku
    Quezado, Martha
    Lebensohn, Alexandra P.
    Aldape, Kenneth
    Agra, Maria
    Wagner, Cathy
    Mallory, Yvonne
    Hassan, Raffit
    Ghafoor, Azam
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (03) : 461 - 466
  • [42] Concomitant Loss of PBRM1 and BAP1 Protein Expression is an Important Prognostic Event in Early Stages of Clear Cell Renal Cell Carcinoma.
    da Cunha, Isabela W.
    da Costa, Walter H.
    Fares, Aline F.
    Bezerra, Stephania M.
    Schultz, Luciana
    Guimaraes, Gustavo C.
    Zequi, Stenio C.
    MODERN PATHOLOGY, 2018, 31 : 336 - 336
  • [43] Further evidence for germline BAP1 mutations predisposing to melanoma and malignant mesothelioma
    Cheung, Mitchell
    Talarchek, Jacqueline
    Schindeler, Karen
    Saraiva, Eduardo
    Penney, Lynette S.
    Ludman, Mark
    Testa, Joseph R.
    CANCER GENETICS, 2013, 206 (05) : 206 - 210
  • [44] Expression and Mutation Patterns of PBRM1, BAP1 and SETD2 Mirror Specific Evolutionary Subtypes in Clear Cell Renal Cell Carcinoma
    Bihr, Svenja
    Ohashi, Riuko
    Moore, Ariane L.
    Ruschoff, Jan H.
    Beisel, Christian
    Hermanns, Thomas
    Mischo, Axel
    Corro, Claudia
    Beyer, Jorg
    Beerenwinkel, Niko
    Moch, Holger
    Schraml, Peter
    NEOPLASIA, 2019, 21 (02): : 247 - 256
  • [45] The impact of PBRM1 and BAP1 expression on outcomes of patients with metastatic renal cell carcinoma (mRCC) treated with VEGF-targeted therapy (TT).
    Fay, Andre Poisl
    de Velasco, Guillermo
    Gray, Kathryn P.
    Ho, Thai Huu
    Song, Jiaxi
    Kapur, Payal
    Albiges, Laurence
    McDermott, David F.
    Heng, Daniel Yick Chin
    Brugarolas, James
    Choueiri, Toni K.
    Signoretti, Sabina
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (02)
  • [46] PBRM1 but not BAP1 deficiency is a frequent feature of multifocal non-cystic low-grade clear cell renal cell carcinoma
    Agaimy, Abbas
    Trpkov, Kiril
    Gao, Yuan
    Hartmann, Arndt
    Hes, Ondrej
    LABORATORY INVESTIGATION, 2019, 99
  • [47] PBRM1 but not BAP1 deficiency is a frequent feature of multifocal non-cystic low-grade clear cell renal cell carcinoma
    Agaimy, Abbas
    Trpkov, Kiril
    Gao, Yuan
    Hartmann, Arndt
    Hes, Ondrej
    MODERN PATHOLOGY, 2019, 32
  • [48] BAP1, PBRM1 and SETD2 in clear-cell renal cell carcinoma: molecular diagnostics and possible targets for personalized therapies
    Piva, Francesco
    Santoni, Matteo
    Matrana, Marc R.
    Satti, Suma
    Giulietti, Matteo
    Occhipinti, Giulia
    Massari, Francesco
    Cheng, Liang
    AntonioLopez-Beltran
    Scarpelli, Marina
    Principato, Giovanni
    Cascinu, Stefano
    Montironi, Rodolfo
    EXPERT REVIEW OF MOLECULAR DIAGNOSTICS, 2015, 15 (09) : 1201 - 1210
  • [49] 透明细胞肾细胞癌组织中PBRM1和BAP1表达缺失对患者预后的影响
    付刚
    王晓敏
    曹波
    现代肿瘤医学, 2024, 32 (11) : 2051 - 2054
  • [50] Differential overall survival results in RECORD-3 study based on three distinct clear cell metastatic renal cell carcinoma molecular subgroups classified by BAP1 and/or PBRM1 mutations
    Hsieh, James
    Chen, David
    Wang, Patricia
    Chen, Ying-Bei
    Mahtab, Marker
    Pate, Parul
    Bhanot, Umesh
    Berger, Michael
    Cheng, Emily
    Knox, Jennifer
    Voss, Martin
    Voi, Maurizio
    Motzer, Robert
    BJU INTERNATIONAL, 2016, 118 : 10 - 10